Summary
Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8–7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
American Cancer Society (1991). Cancer Facts and Figures 1991, American Cancer Society: Atlanta
Anthony, L., Johnson, D., Hande, K., Shaff, M., Winn, S., Krozely, M. & Oates, J. (1993). Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32: 217–223.
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. H. & Pless, J. (1982). SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140.
Buscail, L., Saint-Laurent, N., Chastre, E., Vaillant, J. C., Gespach, C., Capella, G., Kalthoff, H., Lluis, F., Vaysse, N. & Susini, C. (1996). Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56: 1823–1827.
Canobbio, L., Boccardo, F., Cannata, D., Gallotti, P. & Epis, R. (1992). Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 69: 648–650.
Caron, P., Cogne, M., Gusthiot-Joudet, B., Wakim, S., Catus, F. & Bayard, F. (1995). Intramuscular injections of slow release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132: 320–325.
Cascinu, S., Del Ferro, E. & Catalano, G. (1995). A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 71: 97–101.
Ebert, M., Friess, H., Berger, H. G. & Büchler, M. W. (1994). Role of octreotide in the treatment of pancreatic cancer. Digestion 55: (suppl. 1) 48–51.
Glimelius, B., Hoffman, K., Sjöden, P. O., Jacobsson, G., Sellström, H., Enander, L. K., Linne, T. & Svensson, C. (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600.
Hughier, M., Samama, G., Testart, J., Mauban, S., Fingerhut, A., Nassar, J., Houry, S., Saeck, D., De Mestier, I. & Favre, J. P. (1992). Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg 164: 348–353.
Janson, E. T., Gobl, A., Kalkner, K. M. & Oberg, K. (1996). A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56: 2561–2565.
Kiljn, J. G. M., Hoff, A. M., Planting, A. S. T., Verweij, J., Kok, T., Lamberts, S. W. J., Portengen, H. & Foekens, J. A. (1990). Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue sandostatin: a phase II study including endocrine effects. Br J Cancer 62: 627–630.
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W., Kooij, P., Oei, H., Van Hagen, M., Postema, F., De Jong, M. & Reubi, J. C. (1993). Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe-1 and 123I-Tyr-3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716–731.
Kuhn, J. M., Legrand, A., Ruiz, J. M., Obach, R., De-Ronzan, J. & Thomas, F. (1994). Pharmacokinetic and pharmacodynamic properties of a long acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 38: 213–219.
Marek, J., Hana, V., Krsek, M., Justova, V., Catus, F. & Thomas, F. (1994). Long-term treatment of acromegaly with the slow release somatostatin analogue lanreotide. Eur J Endocrinol 131: 20–26.
National Cancer Institute (1991). Annual Cancer Statistics Review 1973–1988, NIH publication no. 91-2789. Department of Health and Human Services: Bethesda, MD
Qin, Y., Schally, A. V. & Willems, G. (1992). Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int J Cancer 52: 791–796.
Reubi, J. C., Horisberger, U., Essed, J. E., Jeekel, J., Klijn, J. G. H. & Lamberts, S. W. J. (1988). Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95: 760–763.
Reubi, J. C., Krenning, E., Lamberts, S. W. J. & Kvols, L. (1990). Somatostatin receptors in malignant tissues. Steroid Biochem Mol Biol 37: 1073–1077.
Reubi, J. C., Horisberger, U. & Laissue, J. (1994). High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumour–host interaction?. Int J Cancer 56: 681–688.
Scatchard, G. (1949). The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672.
Taylor, J. E., Theveniau, M. A., Bashirzadeh, R., Reisine, T. & Eden, P. A. (1994). Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15: 1229–1236.
Viollet, C., Prevost, G., Maubert, E., Faivre-Bauman, A., Gardette, R., Kordon, C., Loudes, C., Slama, A. & Epelbaum, J. (1995). Molecular pharmacology of somatostatin receptors. Fundam Clin Pharmacol 9: 107–113.
Virgolini, I., Yang, Q., Li, S., Angelberger, P., Neumold, N., Niederle, B., Scheithauer, W. & Valent, P. (1994). Cross-competition between vasoactive intestinal peptide (VIP) and somatostatin for binding to tumor cell receptors. Cancer Res 54: 690–700.
Warshaw, A. L. & Fernandez-del Castillo, C. (1992). Pancreatic carcinoma. N Engl J Med 326: 455–465.
Weckbecker, G., Liu, R., Tolcsvai, L. & Bruns, C. (1992). Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52: 4973–4978.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Raderer, M., Hamilton, G., Kurtaran, A. et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer 79, 535–537 (1999). https://doi.org/10.1038/sj.bjc.6690084
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690084
Keywords
This article is cited by
-
Octreotide Uptake in Intracranial Metastasis of Pancreatic Ductal Adenocarcinoma Origin in a Patient with a Prolonged Clinical Course
Digestive Diseases and Sciences (2009)
